US FDA To Sponsors: No Dice On Appealing Advice Through Dispute Resolution

Appeals pathway remains unavailable for challenging regulatory advice on drug and biologic product development programs despite objections from industry; sponsors may approach a higher management level to further discuss such advice in meetings established under the user fee programs, final guidance states.